| Name | Title | Contact Details |
|---|---|---|
Mary Storella |
Vice President and General Counsel | Profile |
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.
Pebble Labs Inc. is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security. Our mission is to develop breakthrough disruptive technologies that address the greatest agricultural, aquacultural, and environmental challenges facing the globe.
Hazel Technologies develops products that extend the shelf life of produce. Our customers include some of the largest produce growers in the world.